Trial evaluates dosing and scheduling of adjuvant administered with personalized immunotherapy.

2003 JAN 8 - (NewsRx.com & NewsRx.net) -- Genitope Corp. has announced promising results of a phase II clinical trial to evaluate dosage and scheduling of an adjuvant which is administered with the company's personalized vaccine-like immunotherapy, GTOP-99, for the treatment of follicular non-Hodgkin lymphoma (fNHL).

The data were presented by Julie Vose, MD, professor of medicine at the University of Nebraska Medical Center, during a poster presentation at the American Society of Hematology's 44th Annual Meeting and Exposition.

The data demonstrate for the first time that an abbreviated course of the adjuvant GM-CSF, recombinant human granulocyte-macrophage colony stimulating factor, which stimulates the immune system, can induce an immune response in fNHL patients when administered with GTOP-99.

"At this point, with 16-22 months of follow-up, more than half of the patients treated with this regimen remain in remission. Follicular NHL is a cancer with no known cure, so we are pleased with these findings and will continue research to improve adjuvant regimens with GTOP-99," said Vose.

In previous and ongoing phase II and phase III ...